Xilio Therapeutics Secures $52M Deal with AbbVie Amid Growth
By ATTN Desk · Editorial oversight: Sean Han
XILIO THERAPEUTICS INC (XLO)
1. Introduction to the Company
Xilio Therapeutics Inc., founded in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies. Leveraging a proprietary, clinically validated platform, Xilio engineers masked biologics—including cytokines, antibodies, and cell engagers—to activate selectively within the tumor microenvironment and minimize systemic toxicity.
2. Corporate Structure
- Public Listing: Nasdaq (Global Select Market) under ticker XLO
- Headquarters: Waltham, Massachusetts
- Founded: 2016
- Employee Count: 51–200 (LinkedIn)
- Key Executives:
- René Russo, Pharm.D., President & CEO
- Uli Bialucha, Ph.D., Chief Scientific Officer
- Caroline Hensley, Chief Legal Officer
3. Recent Developments and News
- February 12, 2025: Entered a collaboration and option-to-license agreement with AbbVie, receiving $52.0 million upfront and eligible for up to $2.1 billion in milestones and royalties.
- March 2024–Ongoing: Advancing XTX301 (tumor-activated IL-12) in a Phase 1 monotherapy trial under an exclusive license with Gilead Sciences.
- May 8, 2025: Reported first-quarter 2025 financial results:
- Cash & equivalents: $89.1 million (vs. $55.3 million on December 31, 2024)
- Collaboration & license revenue: $2.9 million
- R&D expenses: $8.3 million (vs. $10.4 million in Q1 2024)
- G&A expenses: $8.5 million (vs. $6.1 million in Q1 2024)
- Net loss: $13.3 million (vs. $17.2 million in Q1 2024)
- Cash runway projected into Q1 2026
- May 31, 2025 (ASCO Annual Meeting, Chicago): Presented updated Phase 2 data for vilastobart (XTX101)—a tumor-activated, Fc-enhanced anti-CTLA-4—in combination with atezolizumab in metastatic microsatellite stable colorectal cancer (MSS CRC). Key findings included a 27 percent objective response rate in patients without liver metastases and a low incidence of immune-related adverse events.
- Pipeline Progress:
- Vilastobart (XTX101): Partnering discussions underway following preliminary positive safety and efficacy data.
- XTX501 (masked PD-1/IL-2 bispecific): IND-enabling studies; planned IND submission mid-2026.
- Masked T Cell Engagers (ATACR and SEECR formats):
- PSMA program: candidate nomination Q3 2025; IND Q1 2027
- CLDN18.2 program: nomination Q4 2025; IND Q2 2027
- STEAP1 program: nomination H1 2026; IND H2 2027
- June 2, 2025: Filed a preliminary prospectus supplement (424B5) to offer pre-funded warrants and common stock warrants, with underwriting discounts at 6 percent of gross proceeds.
4. Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (June 2, 2025) | $0.75 (−29.91 %) |
| 52-Week Range | $0.62 – $1.70 |
| Volume (June 2, 2025) | 565,641 |
| Intraday Market Cap | $38.8 million |
| Cash & Cash Equivalents (Mar 31, 2025) | $89.1 million |
| Total Debt/Equity (mrq) | 73.5 percent |
| Collaboration & License Revenue (Q1 2025) | $2.9 million |
| R&D Expenses (Q1 2025) | $8.3 million |
| G&A Expenses (Q1 2025) | $8.5 million |
| Net Loss (Q1 2025) | $13.3 million |
| Runway Through | Q1 2026 |
Xilio balances internal R&D with collaborations (Gilead, AbbVie, Roche) to advance its pipeline while managing cash burn. The warrant offering aims to enhance liquidity. Shifts in R&D spending reflect prioritization of later-stage programs (vilastobart, XTX301) and early-stage masked bispecifics.
5. Market Position and Industry Context
- Therapeutic Focus: Tumor-activated biologics designed to localize immune activation and reduce off-target effects.
- Competitive Landscape: Other checkpoint inhibitors, cytokine therapies, and T cell engagers are in development at both larger biopharma and smaller biotech firms.
- Clinical Niche: MSS CRC is classified as an immunologically “cold” tumor type with limited treatment options; preliminary Phase 2 signals for vilastobart aim to address an unmet need.
- Regulatory Milestones: Data presentations at ASCO and upcoming IND submissions will influence valuation and partner interest.
- Investor Sentiment: Low beta (0.02) compared to the S&P 500 suggests limited correlation with broader markets; stock volatility is influenced by clinical results and financing events.
tl;dr
– On May 8, 2025, Xilio reported Q1 results showing $89.1 million in cash, $2.9 million in collaboration revenue, and a $13.3 million net loss, with runway into Q1 2026.
– At ASCO on May 31, vilastobart (XTX101) in MSS CRC patients without liver metastases yielded a 27 percent objective response rate and minimal immune-related toxicity.
– Collaboration agreements include AbbVie ($52 million upfront on Feb 12, 2025) and an ongoing Gilead partnership for XTX301.
– A preliminary prospectus filed June 2 aims to raise additional capital via pre-funded and common stock warrants (6 percent underwriter fee).
– Upcoming milestones: IND submission for XTX501 mid-2026; masked T cell engager candidates slated between Q3 2025 and H1 2026.